Patents by Inventor A. Edward Osawa
A. Edward Osawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210228764Abstract: The present invention provides a hemostatic composite sponge comprising oxidized cellulose and an essentially gelatin-free bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.Type: ApplicationFiled: April 15, 2021Publication date: July 29, 2021Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
-
Patent number: 11071804Abstract: The present invention provides a hemostatic composite sponge comprising oxidized cellulose and an essentially gelatin-free bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.Type: GrantFiled: December 15, 2017Date of Patent: July 27, 2021Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
-
Publication number: 20210220512Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) providing said first component and said second component in a combined form in a final container, c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container, c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container, d) finishing the final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.Type: ApplicationFiled: April 5, 2021Publication date: July 22, 2021Inventors: Andreas Goessl, Atsushi Edward Osawa, Cary J. Reich
-
Patent number: 10994045Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) providing said first component and said second component in a combined form in a final container, c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container, c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container, d) finishing the final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.Type: GrantFiled: February 11, 2019Date of Patent: May 4, 2021Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Andreas Goessl, Atsushi Edward Osawa, Cary J. Reich
-
Publication number: 20190231922Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) providing said first component and said second component in a combined form in a final container, c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container, c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container, d) finishing the final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.Type: ApplicationFiled: February 11, 2019Publication date: August 1, 2019Inventors: Andreas Goessl, Atsushi Edward Osawa, Cary J. Reich
-
Patent number: 10245348Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) providing said first component and said second component in a combined form in a final container, c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container, c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container, d) finishing the final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.Type: GrantFiled: July 20, 2015Date of Patent: April 2, 2019Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Andreas Goessl, Atsushi Edward Osawa, Cary J. Reich
-
Publication number: 20180104377Abstract: The present invention provides a hemostatic composite sponge comprising oxidized cellulose and an essentially gelatin-free bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.Type: ApplicationFiled: December 15, 2017Publication date: April 19, 2018Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
-
Patent number: 9872934Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.Type: GrantFiled: December 1, 2016Date of Patent: January 23, 2018Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
-
Publication number: 20170080119Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.Type: ApplicationFiled: December 1, 2016Publication date: March 23, 2017Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
-
Patent number: 9517287Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a material enhancing the adherence of said sponge to the applied tissue stably associated with at least one surface of said sponge, a method of producing these sponges and their use in hemostasis.Type: GrantFiled: June 30, 2014Date of Patent: December 13, 2016Assignees: Baxter International, Inc., Baxter Healthcare, S.A.Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
-
Patent number: 9408945Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) mixing said first component and said second component under conditions effective to form a wet paste while essentially preventing degradation of the second component by said first component in a final container or transferring said wet paste into a final container, d) freezing and lyophilizing said paste in said container thereby obtaining a dry and stable hemostatic composition comprising said first and said second component in lyophilized form, and e) finishing said dry and stable hemostatic composition in said final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.Type: GrantFiled: June 1, 2011Date of Patent: August 9, 2016Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Andreas Goessl, Atsushi Edward Osawa, Cary J. Reich
-
Publication number: 20150367022Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) providing said first component and said second component in a combined form in a final container, c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container, c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container, d) finishing the final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.Type: ApplicationFiled: July 20, 2015Publication date: December 24, 2015Inventors: Andreas Goessl, Atsushi Edward Osawa, Cary J. Reich
-
Patent number: 9114172Abstract: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.Type: GrantFiled: February 28, 2013Date of Patent: August 25, 2015Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Woonza M. Rhee, Cary J. Reich, A. Edward Osawa, Felix Vega
-
Patent number: 9084728Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) providing said first component and said second component in a combined form in a final container, c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container, c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container, d) finishing the final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.Type: GrantFiled: June 1, 2011Date of Patent: July 21, 2015Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Andreas Goessl, Atsushi Edward Osawa, Cary J. Reich
-
Patent number: 8962025Abstract: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.Type: GrantFiled: August 1, 2007Date of Patent: February 24, 2015Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Woonza M. Rhee, Cary J. Reich, A. Edward Osawa, Felix Vega
-
Publication number: 20140378928Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a material enhancing the adherence of said sponge to the applied tissue stably associated with at least one surface of said sponge, a method of producing these sponges and their use in hemostasis.Type: ApplicationFiled: June 30, 2014Publication date: December 25, 2014Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
-
Patent number: 8771258Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a material enhancing the adherence of said sponge to the applied tissue stably associated with at least one surface of said sponge, a method of producing these sponges and their use in hemostasis.Type: GrantFiled: December 16, 2010Date of Patent: July 8, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
-
Publication number: 20140120078Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: ApplicationFiled: December 9, 2013Publication date: May 1, 2014Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa
-
Publication number: 20140086898Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: ApplicationFiled: August 19, 2013Publication date: March 27, 2014Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa, Zhen Qian
-
Patent number: 8603511Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: GrantFiled: January 18, 2013Date of Patent: December 10, 2013Assignees: Baxter International, Inc., Baxter Healthcare S.A.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa